These results indicate that the inhibition of GSK-3β does not affect the nuclear accumulation of NF-κB p65 but might alter the ability of NF-κB to regulate target gene promoters in ALL cells. The gene discussed is NFKB1; the disease is acute lymphoblastic leukemia.